Navigation Links
Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality

MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Carlos A. Parra has joined the company as Vice President, Quality. He will have responsibilities in the development and execution of quality program strategies for Alexza's manufacturing operations and preclinical / clinical product candidates. Mr. Parra was most recently Vice President, Operations and Quality at Telik, Inc. in Palo Alto, California, where he was employed since June 2002 and was responsible for all aspects of GxP pharmaceutical development and quality operations, including manufacturing development and GCP compliance.

Prior to his tenure at Telik, Mr. Parra was a Principal Partner at West Coast Associates from January 1996 to June 2002. Before founding West Coast Associates, his quality experience spanned 20 years with both small and large pharmaceutical and biotechnology companies. Mr. Parra holds a Bachelor's of Science in Microbiology with a minor in Engineering from the University of Texas at El Paso.

"We are very pleased to welcome Carlos to Alexza to lead our Quality Departments and as a member of our Management Team," said Thomas B. King, Alexza President and CEO. "The continued rapid growth of our clinical and preclinical programs at Alexza requires us to add integrated GLP and GCP quality systems and procedures to our existing GMP program. Carlos brings a wealth of U.S. and international quality expertise to Alexza, and we look forward to his contributions to our future development."

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
3. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
4. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
5. Nick Childs Joins Grey New York as Director of Content Development
6. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
7. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
8. NASN Joins Partnership to Fight Chronic Disease
9. AstraZeneca Joins Local Walking Movement
10. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
11. Fund Manager Joins Board of GSI Securitization Inc.
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just ... is offering customers 10% off of their purchase of lice treatment product. In addition, ... price. According to a company spokesperson. “Finding lice is a sure way to ruin ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think ... customers choose to buy during the Black Friday and Cyber Monday massage chair ... to search the Internet high and low to find the best massage chair deals, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology: